01 NPHLA Intelligence desk

Metabolic & Weight-Loss Intelligence

For weight-loss clinics, med spas, pharmacists, prescribers, medical directors and metabolic-health operators: what is changing in GLP-1 and next-generation obesity medicine — and what it could mean for your practice.

How this desk works

Trending on this desk

Signal strength reflects editorial attention across tracked sources — not medical certainty or strength of evidence.

Diabetes developments17 tracked items this week · 6 sources
High attention
Obesity drug pipeline12 tracked items this week · 6 sources
High attention
Tirzepatide11 tracked items this week · 4 sources
High attention
Lean mass & body composition8 tracked items this week · 5 sources
Building
Semaglutide9 tracked items this week · 4 sources
Building
Orforglipron3 tracked items this week · 2 sources
Emerging

Trial watch

Active, not recruitingPhase 1NCT07407348
A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body
Boehringer Ingelheim. Conditions: Healthy; Obesity; Overweight. Investigational — not approved for the use studied.
Not yet recruitingPhase 1NCT07935200
Safety and Pharmacokinetics of UI112 Compared With UIC202611 in Healthy Adults
Korea United Pharm. Inc.. Conditions: Bioequivalence; Pharmacokinetics. Investigational — not approved for the use studied.
Not yet recruitingPhase 1NCT07936058
A Phase I Study to Evaluate the Food Effect on Ecnoglutide Tablet
Hangzhou Sciwind Biosciences Co., Ltd.. Conditions: Food Effect in Healthy Volunteers; Weight Management. Investigational — not approved for the use studied.
Not yet recruitingNot applicableNCT07936838
Effects of a Gut-Active Peptide That Stimulates GLP-1 Release on Appetite and Satiety in Healthy Adults With Overweight
Lembas. Conditions: Appetite and Hunger, Suppression; Satiety and Appetite; Weight Change; Gastrointestinal Symptoms; Body Composition. Investigational — not approved for the use studied.

All trials

Recurring formats

GLP-1 DailyThe day’s meaningful GLP-1 developments in one place.
Pipeline WatchObesity and metabolic drugs moving through development.
Trial WatchTrials that start, change status or post results.
What Changed TodayEvery new official record on this desk since yesterday.
Drug Development RadarEarly signals from research and development.
The 60-Second Metabolic BriefOne development, explained in a minute.

Around the industry

News reportMedPage TodayNov 10, 2026
GLP-1 Pill Shows Benefit in Sleep Apnea (opens the source in a new tab)
News reportSTATNov 10, 2026
STAT+: Former Eli Lilly rep claims she was fired for complaining about marketing of Mounjaro diabetes drug (opens the source in a new tab)
News reportPharmacy TimesNov 10, 2026
Beyond Weight Loss: Survodutide's Cardiometabolic Effects (opens the source in a new tab)
News reportPharmacy TimesNov 10, 2026
Lilly–Hims & Hers GLP-1 Deal Tests Whether Convenience Can Deliver Continuity of Care (opens the source in a new tab)
News reportPharmacy TimesNov 9, 2026
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk (opens the source in a new tab)
News reportSTATNov 9, 2026
STAT+: Eli Lilly’s GLP-1 pill Foundayo helped alleviate sleep apnea in studies (opens the source in a new tab)

Metabolic & Weight-Loss Intelligence

Archive

What changed today in Metabolic: 2 trial updates, 1 new study

What changed today in Metabolic: 3 trial updates, 2 new studies

What changed today in Metabolic: 1 new study

What changed today in Metabolic: 1 new study

What changed today in Metabolic: 3 trial updates

What changed today in Metabolic: 4 new studies, 3 trial updates

What changed today in Metabolic: 2 new studies

What changed today in Metabolic: 1 new study

What changed today in Metabolic: 9 trial updates

What changed today in Metabolic: 1 new study

What changed today in Metabolic: 1 new study

What changed today in Metabolic: 6 trial updates, 1 new study